Corrigendum Open Access | 10.1172/jci.insight.165502
Find articles by Lowe, M. in: JCI | PubMed | Google Scholar
Find articles by Naik, H. in: JCI | PubMed | Google Scholar
Find articles by Clancy, S. in: JCI | PubMed | Google Scholar
Find articles by Pauli, M. in: JCI | PubMed | Google Scholar
Find articles by Smith, K. in: JCI | PubMed | Google Scholar
Find articles by Bi, Y. in: JCI | PubMed | Google Scholar
Find articles by Dunstan, R. in: JCI | PubMed | Google Scholar
Find articles by Gudjonsson, J. in: JCI | PubMed | Google Scholar
Find articles by Paul, M. in: JCI | PubMed | Google Scholar
Find articles by Harris, H. in: JCI | PubMed | Google Scholar
Find articles by Kim, E. in: JCI | PubMed | Google Scholar
Find articles by Shin, U. in: JCI | PubMed | Google Scholar
Find articles by Ahn, R. in: JCI | PubMed | Google Scholar
Find articles by Liao, W. in: JCI | PubMed | Google Scholar
Find articles by Hansen, S. in: JCI | PubMed | Google Scholar
Find articles by Rosenblum, M. in: JCI | PubMed | Google Scholar
Published October 24, 2022 - More info
Hidradenitis suppurativa (HS) is a highly prevalent, morbid inflammatory skin disease with limited treatment options. The major cell types and inflammatory pathways in skin of patients with HS are poorly understood, and which patients will respond to TNF-α blockade is currently unknown. We discovered that clinically and histologically healthy appearing skin (i.e., nonlesional skin) is dysfunctional in patients with HS with a relative loss of immune regulatory pathways. HS skin lesions were characterized by quantitative and qualitative dysfunction of type 2 conventional dendritic cells, relatively reduced regulatory T cells, an influx of memory B cells, and a plasma cell/plasmablast infiltrate predominantly in end-stage fibrotic skin. At the molecular level, there was a relative bias toward the IL-1 pathway and type 1 T cell responses when compared with both healthy skin and psoriatic patient skin. Anti–TNF-α therapy markedly attenuated B cell activation with minimal effect on other inflammatory pathways. Finally, we identified an immune activation signature in skin before anti–TNF-α treatment that correlated with subsequent lack of response to this modality. Our results reveal the fundamental immunopathogenesis of HS and provide a molecular foundation for future studies focused on stratifying patients based on likelihood of clinical response to TNF-α blockade.
Margaret M. Lowe, Haley B. Naik, Sean Clancy, Mariela Pauli, Kathleen M. Smith, Yingtao Bi, Robert Dunstan, Johann E. Gudjonsson, Maia Paul, Hobart Harris, Esther Kim, Uk Sok Shin, Richard Ahn, Wilson Liao, Scott L. Hansen, Michael D. Rosenblum
Original citation: JCI Insight. 2020;5(19):e139932. https://doi.org/10.1172/jci.insight.139932
Citation for this corrigendum: JCI Insight. 2022;7(20):e165502. https://doi.org/10.1172/jci.insight.165502
The authors recently became award of inconsistencies in Figure 9, C and D, and have identified an error in which the data from a nonresponder had been inadvertently plotted in the responder column. The correct figure parts are below. The HTML and PDF versions have been updated online. The authors have stated that all conclusions of the paper remain the same.
The authors regret the errors.
See the related article at Immunopathogenesis of hidradenitis suppurativa and response to anti-TNFα therapy.